Talphera (NASDAQ:TLPH) Raised to “Strong-Buy” at Maxim Group

Talphera (NASDAQ:TLPH) was upgraded by analysts at Maxim Group to a “strong-buy” rating in a research note issued on Friday,Zacks.com reports.

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Friday, August 16th.

Talphera Trading Down 2.0 %

TLPH opened at $0.89 on Friday. The company has a market cap of $15.12 million, a PE ratio of -1.39 and a beta of 0.31. The company has a 50 day moving average of $0.91 and a 200 day moving average of $0.94. Talphera has a 12 month low of $0.43 and a 12 month high of $1.61.

Talphera (NASDAQ:TLPH) last posted its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Research analysts forecast that Talphera will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Talphera

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC bought a new stake in shares of Talphera during the 2nd quarter worth $1,773,000. Rosalind Advisors Inc. bought a new stake in Talphera during the third quarter worth about $650,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of Talphera in the 2nd quarter worth about $64,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.